RedHill Biopharma (RDHL) Enterprise Value: 2011-2025
Historic Enterprise Value for RedHill Biopharma (RDHL) over the last 12 years, with Jun 2025 value amounting to -$2.1 million.
- RedHill Biopharma's Enterprise Value fell 115.92% to -$2.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$12.9 million, marking a year-over-year increase of 46.23%. This contributed to the annual value of $1.9 million for FY2024, which is 214.11% up from last year.
- Latest data reveals that RedHill Biopharma reported Enterprise Value of -$2.1 million as of Q2 2025, which was down 213.19% from $1.9 million recorded in Q4 2024.
- In the past 5 years, RedHill Biopharma's Enterprise Value ranged from a high of $251.3 million in Q1 2021 and a low of -$13.6 million during Q4 2022.
- Moreover, its 3-year median value for Enterprise Value was -$1.9 million (2023), whereas its average is -$1.6 million.
- Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 137.64% in 2023, then soared by 259.75% in 2024.
- Quarterly analysis of 5 years shows RedHill Biopharma's Enterprise Value stood at $90.8 million in 2021, then crashed by 115.02% to -$13.6 million in 2022, then surged by 87.93% to -$1.6 million in 2023, then soared by 214.11% to $1.9 million in 2024, then slumped by 115.92% to -$2.1 million in 2025.
- Its Enterprise Value stands at -$2.1 million for Q2 2025, versus $1.9 million for Q4 2024 and $13.4 million for Q2 2024.